Dutch doctors resist pharma firm’s 500-fold price hike
pharmafile | September 3, 2018 | News story | Sales and Marketing | Netherlands, leadiant, pharma, pricing
A group of Dutch doctors and health advocates are taking action against the Italian pharmaceutical firm Leadiant Biosciences who have increased the price of a lifesaving drug by 500 times its original price.
The Dutch Pharmaceutical Accountability Foundation, a non-profit organisation set up to tackle high drug prices in the Netherlands is set to file a claim against the price hiking firm with The Netherlands’ Authority for Consumers and Markets.
Lediant are accused of having abused their market power after they increased the price of their drug chenodeoxycholic acid (CDCA) from €300 a year to €150,000 each year after they gained full control of supplies and approval for the treatment of the rare disease cerebrotendinous xanthomatosis (CTX) from EU regulators in 2017.
Separately, doctors treating CTX at the Amsterdam Medical Center are seeking to develop a low cost version of the drug in an effort to undercut the Italian company. The case is anticipated to spark fresh debate around orphan drug legislation which allows manufacturers to win exclusivity on drugs that have been approved for the treatment of rare diseases, even after patents have expired.
Although CDCA is a relatively simple chemical compound, Leadiant Biosciences acquired rival suppliers and withdrew the drug from the market. While CDCA had been prescribed by Dutch doctors off label for the treatment of CDCA, Leadiant relaunched the drug after gaining approval for the treatment of CTX. This effectively gave them a monopoly which allowed them to raise prices to astronomical levels.
Carla Hollak from the Amsterdam Medical Centre commented: “This is essential medication. I’m fully against these kind of actions by the pharmaceutical industry to gain a monopoly and sell a drug for a price that suggests it has cost an enormous amount.”
Louis Goss
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
